Clinical Trial Update: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update for ineibilizumab in neuromyelitis optica spectrum disorders is in progress, with status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Inebilizumab (inebilizumab)

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Neuromyelitis Optica Spectrum Disorders | Phase 4 | Status: UNKNOWN